Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Molecular Research Pharmact S R L maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The data shows 1 pending office action currently active. This workload is assigned to 1 distinct examiner and is located within 1 distinct art unit. The busiest examiner for the portfolio is VAJDA, KRISTIN ANN, who is handling 1 pending office action. This action represents the total pending workload for the company at the patent office.
Because the portfolio involves 1 distinct examiner and 1 distinct art unit, the prosecution process is handled by this individual in this technical group. This means the outcomes for the pending matter are subject to the review standards of VAJDA, KRISTIN ANN. For a practitioner, this concentration in the art unit indicates that the technical subject matter is being evaluated within that group. The presence of 1 pending office action suggests the company is in a specific stage of its patenting process. This data provides a point of contact for the company's current legal interactions. The results for the portfolio are tied to the examination patterns of the examiner involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VAJDA, KRISTIN ANN | 1 | 84.0% | +10.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18553514 | BENZOMORPHAN DERIVATE FOR USE IN THERAPY | VAJDA, KRISTIN ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18553514 | BENZOMORPHAN DERIVATE FOR USE IN THERAPY | VAJDA, KRISTIN ANN | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18553514 | BENZOMORPHAN DERIVATE FOR USE IN THERAPY | VAJDA, KRISTIN ANN | 1622 | §102§103§112 | Non-Final OA | — | Pending | Sep 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial